Free Trial

Repligen (RGEN) Stock Forecast & Price Target

$120.08
-0.69 (-0.57%)
(As of 07/5/2024 ET)

Repligen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$193.00
60.73% Upside
High Forecast$220.00
Average Forecast$193.00
Low Forecast$155.00
TypeCurrent Forecast
7/7/23 to 7/6/24
1 Month Ago
6/7/23 to 6/6/24
3 Months Ago
4/8/23 to 4/7/24
1 Year Ago
7/7/22 to 7/7/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$193.00$197.75$196.70$207.44
Forecasted Upside60.73% Upside18.83% Upside17.34% Upside20.10% Upside

RGEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RGEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Repligen Stock vs. The Competition

TypeRepligenMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside60.73% Upside995.27% Upside12.26% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/26/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$180.00 ➝ $155.00+25.86%
6/18/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
5/2/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$230.00 ➝ $200.00+22.79%
2/22/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$165.00 ➝ $207.00+6.84%
2/15/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$210.00 ➝ $220.00+6.10%
12/4/2023Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
[Urgent] Hedge Funds Expect Major Crypto Moves (Ad)

In the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all…

Click here to register now.
11/2/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$210.00 ➝ $170.00+24.51%
11/1/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$207.00 ➝ $200.00+53.46%
8/3/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$207.00 ➝ $200.00+16.73%
8/3/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$180.00 ➝ $200.00+17.32%
7/20/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$185.00+16.65%
1/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$230.00 ➝ $200.00+28.15%
11/2/2022William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Larew
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:43 AM ET.

RGEN Forecast - Frequently Asked Questions

What is Repligen's forecast for 2024?

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Repligen is $193.00, with a high forecast of $220.00 and a low forecast of $155.00.

Should I buy or sell Repligen stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares.

Does Repligen's stock price have much upside?

According to analysts, Repligen's stock has a predicted upside of 19.43% based on their 12-month stock forecasts.

Has Repligen been upgraded by Wall Street analysts recently?

Over the previous 90 days, Repligen's stock had 1 upgrade by analysts.

What analysts cover Repligen?

Repligen has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Guggenheim, and JPMorgan Chase & Co. in the past 90 days.

Do Wall Street analysts like Repligen more than its competitors?

Analysts like Repligen more than other "medical" companies. The consensus rating score for Repligen is 2.82 while the average consensus rating score for "medical" companies is 2.71. Learn more on how RGEN compares to other companies.


This page (NASDAQ:RGEN) was last updated on 7/6/2024 by MarketBeat.com Staff

From Our Partners